Shots:
- The P-III ADVANCE trial evaluates efficacy, safety & tolerability of atogepant (PO, 10/30/60 mg, qd) vs PBO in 910 patients with EM who experienced 4-14 migraine days/mos.
- Results: patients achieving a ≥50% reduction in monthly migraine days (55.6%/58.7%/60.8% vs 29.0%) @12wks. & all doses were well tolerated. Additionally, 30/60 mg doses showed improvements in all six 2EPs, including a reduction in acute medication use & function impairment measures in AIM-D & MSQ v2.1
- Atogepant is a CGRP receptor antagonist. If approved, it will be 1st oral gepant for EM & is currently under FDA’s review with an expected regulatory decision in late Q3’21
Click here to read full press release/ article | Ref: AbbVie | Image: Wall Street Journal
The post AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM first appeared on PharmaShots.
